More on EYPT

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-10.6% Growth)
- Ratings (9.4 Score)

Upcoming Events

- Earnings (8/5/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

EyePoint Pharmaceuticals (NQ:EYPT)
Delayed: 13.58 +0.43 (3.27%)
Prev. Close $13.15  
Open$13.53 
52 Wk High$ 
52 Wk Low$ 
Day High$14.03 
Day Low$13.26 
P/E N/A  
EPS$ 
Volume1,290,270 

Friends, Peers and Foes (?): APLS, BIIB, DASH, EHC, GKOS (more...)

Jun 16, 2026 07:00 AM EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jun 3, 2026 04:40 PM Form SCHEDULE 13G EyePoint, Inc. Filed by: Commodore Capital LP
May 27, 2026 04:06 PM Form 4 EyePoint, Inc. For: May 25 Filed by: Elston George
May 19, 2026 07:00 AM EyePoint Announces Participation at Upcoming Investor Conferences
May 18, 2026 07:00 AM EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 15, 2026 04:33 PM Form SCHEDULE 13G/A EyePoint, Inc. Filed by: Paradigm Biocapital Advisors LP
May 14, 2026 07:05 AM Form 8-K EyePoint, Inc. For: May 14
May 14, 2026 07:01 AM EyePoint gets third positive safety review for wet AMD drug trials
May 14, 2026 07:01 AM EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data
May 13, 2026 09:05 AM Form SCHEDULE 13G/A EyePoint, Inc. Filed by: Adage Capital Management, L.P.
View All Articles

Entities mentioned with EYPT

View All Entities